

Figure 1 - Main efficacy analysis - Mean HbA1c (%) by visit during the main 6-month on-treatment period - mITT population




# subjects				
HOE901-U300	391	382	362	391
Lantus	394	382	364	394

Figure 2 -Other secondary efficacy endpoints - Mean average pre-injection SMPG (mmol/L) by visit during the main 6-month on-treatment period -mITT population




# subjects								
HOE901-U300	366	381	379	374	370	359	349	401
Lantus	361	366	370	366	357	337	336	398

Figure 3 - Other secondary efficacy endpoints - Mean 8-point SMPG profile (mmol/L) at baseline and Month 6 endpoint - mITT population



# subjects								
U300 baseline	333	343	335	337	336	338	331	324
Lantus baseline	323	333	326	331	325	333	327	325
U300 M6(LOCF)	333	343	335	337	336	338	331	324
Lantus M6(LOCF)	323	333	326	331	325	333	327	325


Figure 4 - Other secondary efficacy endpoints - Average daily basal insulin and mealtime insulin dose (U) by visit during the main 6-month on-treatment period-mITT population



 # subjects


U-300 basal	404	400	396	392	382	378	371	404
Lantus basal	400	392	390	386	381	374	366	400
U-300 mealtime	384	400	396	389	380	371	365	404
Lantus mealtime	381	389	389	381	378	366	362	400

Figure 5 - Main efficacy analysis - Mean HbA1c (%) by visit during the main 6-month on-treatment period - mITT population




# subjects				
HOE901-U300	386	361	333	386
Lantus	392	373	341	392

Figure 6 - Other secondary efficacy endpoints - Mean average pre-injection SMPG (mmol/L) by visit during the main 6-month on-treatment period - mITT population




# subjects								
HOE901-U300	353	343	338	319	310	301	280	353
Lantus	350	340	340	327	321	292	285	350

Figure 7 - Other secondary efficacy endpoints - Mean 8-point SMPG profile (mmol/l) at baseline and Month 6 endpoint - mITT population




# subjects								
U300baseline	338	347	341	344	339	347	338	325
Lantusbaseline	328	338	328	332	328	336	327	303
U300M6(LOCF)	338	347	341	344	339	347	338	325
LantusM6(LOCF)	328	338	328	332	328	336	327	303

Figure 8 - Other secondary efficacy endpoints - Average daily basal insulin dose (U) by visit during the main 6-month on-treatment period - mITT population




# subjects								
HOE901-U300	402	396	387	374	363	353	339	402
Lantus	403	399	392	382	375	355	349	403

Figure 9 - Main efficacy analysis - Mean HbA1c (%) by visit during the 3-month comparative regimen period - mITT sub-study population



# subjects			
Adapt(N=55)	55	55	55
Fixed(N=54)	52	52	52

Figure 10 - Average daily basal (glargine) and mealtime insulin dose (U) by visit during the 3-month comparative regimen period - mITT sub-study population



# subjects				
Adaptable basal(N=55)	55	54	55	55
Fixed basal(N=54)	53	52	53	53
Adaptable mealtime(N=55)	54	52	54	54
Fixed mealtime(N=54)	52	48	52	52

Figure 11 - Plot of average glucose (mg/dL) by hour of day during entire treatment period - CGM population




Figure 12 - Plot of average glucose (mg/dL) by hour of day during entire morning injection period - CGM population




Figure 13 - Plot of average glucose (mg/dL) by hour of day during entire evening injection period - CGM population






Figure 14 - Main efficacy analysis - Mean HbA1c (%) by visit during the 3-month comparative regimen period - mITT sub-study population



# subjects			
Adapt(N=44)	40	40	40
Fixed(N=42)	37	37	37

Figure 15 - Average daily basal (glargine) insulin (U) by visit during the 3-month comparative regimen period - mITT sub-study population



# subjects				
Adaptable(N=44)	39	39	37	39
Fixed(N=42)	40	35	38	40